SAMUEL D. SPIVACK, M.D.
Since its approval by the Food and Drug Administration (FDA) in 1969 procarbazine has had an established role as a single agent in combination chemotherapy of Hodgkin's disease. The drug offers some benefits for patients with lymphomas of other than Hodgkin's type and small and large cell carcinomas of lung, but there has been no documented enlargement of the role of procarbazine beyond these applications during the past 5 years. Toxicities are hematologic and neurologic, and there are also potential adverse effects in multiple drug interactions and in possible carcinogenesis. Procarbazine should therefore be used only against malignant disease by clinicians experienced in its use and cognizant of potential adverse effects.
Learn more about subscription options.
Register Now for a free account.
SPIVACK SD. Drugs Five Years Later: Procarbazine. Ann Intern Med. 1974;81:795–800. doi: 10.7326/0003-4819-81-6-795
Download citation file:
Published: Ann Intern Med. 1974;81(6):795-800.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only